MedTrace Logo

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

NCT01653028 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2017-11-30

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well alisertib works in treating patients with sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Myxofibrosarcoma
  • Recurrent Adult Soft Tissue Sarcoma
  • Recurrent Leiomyosarcoma
  • Recurrent Liposarcoma
  • Recurrent Malignant Peripheral Nerve Sheath Tumor
  • Recurrent Undifferentiated Pleomorphic Sarcoma
  • Stage III Soft Tissue Sarcoma AJCC v7
  • Stage IV Soft Tissue Sarcoma AJCC v7

Interventions

DRUG

Alisertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Mark Dickson · Alliance for Clinical Trials in Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-22
Primary Completion
2015-08-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01653028 on ClinicalTrials.gov